Dedicated to Global Health, MedinCell is an independent, self-funded and employee-owned company. Free of external financial interests, we incorporate scientific and humanitarian goals into our business as long-term strategic objectives. As a hybrid organization, we work simultaneously on for-profit and non-profit activities with our high-value network of partners.
Skills and commitment of our employees from all around the world are the core value of MedinCell. To attract and retain the best talents in the biotechnological and pharmaceutical industry, we offer a proactive and creative environment where individuals can participate and contribute to the overall success of the company.
Power of the Group
Trust and Respect
Transparency and Directness
2002 > 2010
Research & Development
Patent application for the BEPO™ drug delivery technology filed in 70 countries
Launch of the BEPO™ technology platform
“On the Rise Company” – Drug Delivery Partnerships (Miami)
2012 – present
Collaboration agreements in many fields: contraception, schizophrenia, depression, obstetrics, intra-articular, intravitreal, HIV, parasitology, pain, anaesthetic, etc.
Start of humanitarian collaborations
1st multi-API agreement with a major pharma
BEPO™ US Patent issued
Joint Venture CM Biomaterials formed with Corbion for polymer supply
Multi-API agreement with Sandoz, a Novartis Subsidiary
Second facility in Jacou – France
3 rue des Frères Lumière
One Broadway, 14th Floor
Cambridge, MA 02142